Finance

Lists
CBIO:NASDAQ
Crescent Biopharma Inc
$ 14.32
+0.42%
(+0.060) 1D
$ 14.32
0.00% (0.00)
After hours
Closed: 10-р сарын 2, 16:00:01 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CBIO...
Open
$ 14.48
High
$ 14.55
Low
$ 14.07
Mkt. cap
531.90 сая
Avg. vol.
447.46 мян
Volume
283.27 мян
52-wk high
$ 27.41
52-wk low
$ 8.72
EPS
-$ 7.41
Beta
1.27
Shares outstanding
37.14 сая
No. of employees
69
Open
$ 14.48
High
$ 14.55
Low
$ 14.07
Mkt. cap
531.90 сая
Avg. vol.
447.46 мян
Volume
283.27 мян
52-wk high
$ 27.41
52-wk low
$ 8.72
EPS
-$ 7.41
Beta
1.27
Shares outstanding
37.14 сая
No. of employees
69
News stories
From web sources and news partners
About Crescent Biopharma Inc
CEO-
Employees69
Founded2024
HeadquartersWaltham, Массачусеттс, Америкийн Нэгдсэн Улс
Sector-
Websitecrescentbiopharma.com
Analyst ratings
Based on 4 analysts giving stock ratings to CBIO in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CBIO in the last 3 months.
Highest
Current $ 14.32
$ 28.00 (+95.53%)
Average
$ 27.67 (+93.23%)
Lowest
$ 27.00 (+88.55%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Driscoll
Wedbush
Buy
Maintained
$ 27.00
+88.5%
09/14/2026
Unknown Analyst
Wedbush
Buy
Maintained
$ 27.00
+88.5%
09/14/2026
Mitchell Kapoor
H.C. Wainwright
Hold
Reiterated
-
-
07/31/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$ 28.00
+95.5%
07/31/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
$ 28.00
+95.5%
07/30/2026
Biren Amin
Piper Sandler
Buy
Maintained
$ 35.00
+144.4%
06/23/2026
Bradley Canino
Guggenheim
Buy
Maintained
$ 35.00
+144.4%
04/29/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
04/29/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
-
10.84 сая
1.04 сая
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
20.35 сая
95.03 сая
17.90 сая
19.39 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.54 сая
7.31 сая
7.86 сая
8.74 сая
Operating expense
25.88 сая
102.34 сая
25.77 сая
28.13 сая
Total operating expenses
25.88 сая
102.34 сая
25.77 сая
28.13 сая
Operating income
-25.88 сая
-91.49 сая
-24.73 сая
-28.13 сая
Other non operating income
-
-
-
-
EBT including unusual items
-24.61 сая
-90.40 сая
-23.28 сая
-24.84 сая
EBT excluding unusual items
-24.61 сая
-90.40 сая
-23.28 сая
-26.61 сая
Income tax expense
-
2.00 сая
-
-
Effective tax rate
-
-2.21%
-
-
Other operating expenses
-
-
-
-
Net income
-24.61 сая
-92.40 сая
-23.28 сая
-24.84 сая
Net profit margin
-
-852.06%
-2,240.90%
-
Earnings per share
-1.37
-4.92
-0.70
-0.62
Interest and investment income
1.28 сая
1.10 сая
1.45 сая
1.53 сая
Interest expense
-
-
-
-
Net interest expenses
1.28 сая
1.10 сая
1.45 сая
1.53 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
-25.86 сая
-91.44 сая
-24.66 сая
-28.07 сая
Gain or loss from assets sale
-
-
-
-1.77 сая
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google аппс